Clinical Trial · NCT03116945

Novel Gallium Imaging in Hepatocellular Carcinoma

Overview

The aim of the present study is to validate the uptake of novel, positron emitting radiotracer, 68Gallium Citrate in hepatocellular carcinoma(HCC). The investigators also aim to evaluate the sensitivity of 68Gallium (68Ga)-citrate positron emission tomography/computed tomography (PET/CT) for the identification of intrahepatic HCC lesions in comparison with existing modalities: computed tomography (CT) alone and magnetic resonance imaging (MRI). The investigators expect that 68Ga-citrate PET/CT will offer a sensitive functional imaging modality for identification of HCC lesions in the liver. The investigators intend to use the results of this preliminary study to fuel further studies in the utility of 68Ga-citrate PET/CT for HCC treatment monitoring.

Sponsor

Unknown Organization

Phase

Phase 2

Contacts

Nasrin Ghesani, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03116945

Eligibility

Inclusion

At least one biopsy-confirmed or Liver Imaging Reporting and Data System (LI-RADS)- 5 HCC lesion, diagnosed within the past 6 weeks.
At least one triple-phase CT or MRI of the liver prior to medical or surgical therapy
Lesion size greater than or equal to 3cm

Exclusion

Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study.
Known or suspected hypersensitivity to metals or gallium
Prior medical or surgical therapy for HCC, including chemoembolization, radiofrequency ablation, and lobectomy
Inability to consent
Pregnant or breast-feeding women.